Accelerating PERx reaction enables covalent nanobodies for potent neutralization of SARS-CoV-2 and variants
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
Article activity feed
-
-
SciScore for 10.1101/2022.03.11.483867: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The protein band was detected with HRP-conjugated anti-Hisx6 antibody (Proteintech, #HRP-66005). anti-Hisx6suggested: NoneExperimental Models: Cell Lines Sentences Resources The mixture was diluted 50 times with HBSS and incubated at 37 °C for 1 h, 100 μL of which was subsequently added to 1.5 × 105 ACE2-expressing 293T cells and incubated at 37 °C for 1 h. 293Tsuggested: NoneThe virus stocks were prepared in Vero E6 (ATCC) and titers were determined by plaque assays on Vero-E6 cells. Vero E6SciScore for 10.1101/2022.03.11.483867: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources The protein band was detected with HRP-conjugated anti-Hisx6 antibody (Proteintech, #HRP-66005). anti-Hisx6suggested: NoneExperimental Models: Cell Lines Sentences Resources The mixture was diluted 50 times with HBSS and incubated at 37 °C for 1 h, 100 μL of which was subsequently added to 1.5 × 105 ACE2-expressing 293T cells and incubated at 37 °C for 1 h. 293Tsuggested: NoneThe virus stocks were prepared in Vero E6 (ATCC) and titers were determined by plaque assays on Vero-E6 cells. Vero E6suggested: RRID:CVCL_XD71)Vero-E6suggested: NoneNeutralizing assays were performed in 293T-ACE2 cells (15,000 cells per well) in a white opaque 96-well plates. 293T-ACE2suggested: NoneRecombinant DNA Sentences Resources Nanobody expression and purification: Plasmid pBAD-H11D4, pBAD-MR17K99Y, or pBAD-SR was transformed into E. coli BL21(DE3) for wildtype protein expression. pBAD-SRsuggested: NonePlasmid pBAD-H11D4 (27TAG), pBAD-H11D4 (30TAG), pBAD-H11D4 (100TAG), pBAD-H11D4 (112TAG), pBAD-H11D4 (115TAG), pBAD-H11D4 (116TAG), pBAD-MR17K99Y (99TAG), pBAD-MR17K99Y (101TAG), pBAD-SR4 (37TAG), pBAD-SR4(54TAG), or pBAD-SR4 (57TAG) was co-transformed respectively with plasmid pEVOL-FSYRS into E. coli BL21(DE3) for FSY incorporated protein expression. pBAD-H11D4suggested: NonepBAD-MR17K99Ysuggested: NonepBAD-SR4suggested: NonepEVOL-FSYRSsuggested: NoneThe cells were transfected with 25 μg pcDNA-ACE2-34TAG and 25 μg pMP-FSYRS plasmids according to manufacturer’s protocol. pcDNA-ACE2-34TAGsuggested: NonepMP-FSYRSsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:A potential caveat is that the cross-linking rate can be negatively impacted when the binding affinity between protein drug and target decreases drastically due to target mutation, such as mNb6(108FFY) and Beta RBD. In rare cases, mutation can even occur at the cross-linking residue, which would abolish cross-linking at that site. However, as we demonstrated here and previously,19 44 PERx is a general strategy that can be applied on diverse nanobodies and each nanobody can have FFY incorporated at multiple sites to target different natural residues on Spike RBD to achieve crosslink (Figure 3). Therefore, other nanobodies able to bind mutated Spike RBD could be similarly engineered, and diverse covalent nanobodies could be used in combination to ensure the cross-linking and inhibition of future potential variants. When in use, the irreversible cross-linking ability together with multi-targeting of these covalent nanobodies should achieve complete viral inhibition and mechanistically prevent drug resistance. Nonetheless, animal tests and clinical trial are warranted to confirm these potential benefits of covalent protein drugs. Fast reaction kinetics would be critical for effective inhibition of viral infection, as it enables covalent crosslinks to promptly form between the protein drug and the target within a shorter contact time, and to reach higher extent for more effective neutralization. By introducing electron withdrawing fluorine substitution we designed and genetically ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- No funding statement was detected.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-